New metabolic vulnerabilities of subsets of triple-negative breast cancer discovered

new metabolic vulnerabilities of subsets of triple negative breast cancer discovered

Sumary of New metabolic vulnerabilities of subsets of triple-negative breast cancer discovered:

  • Researchers have identified a metabolic enzyme and pathway in some triple-negative breast cancer (TNBC) patients, which they hope could serve as a biomarker to select patients to receive targeted therapy.
  • Hence, DLST expression could serve as the biomarker to select TNBC patients to receive CPI-613, a drug currently in clinical trial for treating other cancers.
  • ” Hui Feng, MD, PhD, corresponding author, associate professor of pharmacology and medicine at Boston University School of Medicine Researchers in the Feng lab analyzed human patient TNBC samples, human cell lines, including those injected into animals to define the contribution of DLST to TNBC pathogenesis.
  • “Due to current challenges in treating triple-negative breast cancer, our studies suggest that a fraction of patients with aggressive tumors can benefit from CPI-613, a drug disrupting the TCA cycle if their tumor cells have high DLST expression,” said Feng.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close